AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01544309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.~(When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin \[RSV\] dose of 10 mg.)
Study NCT04691336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational and Training with counselling
Description: The nurse conducts a structured interview that covers the following areas: information on respiratory attraction and the symptom of dyspnea, expectations and beliefs about oxygen therapy, use of oxygen therapy, healthy habits, social support. It also evaluates the patient's perception of oxygen therapy, and the level of dyspnea using the mMRC scale. After this, the nurse evaluates the current level of adherence, and if she considers that the patient needs a reinforcement session, she schedules a workshop with 3 other patients and their main caregivers. This workshop takes place 30 days after this interview. In other patients, depending on the level of adherence, a support call is made, and all patients are visited again at the center at 90 days, performing the same evaluation with a structured interview and the scales that were made on day 1
Study NCT02971995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET Scan ou TEP-TDM
Description: Performance of the PET/CT using Flurocholine in order to detect the localization of the pathological fixation of the tracer and to determine the place where to take the biopsy
Study NCT02971995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mpMRI
Description: Performance of the mpMRI in order to determine the place where to take the biopsy
Study NCT01940692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5g intravenous Exacyl
Description: intravenous administration of 1.5g Exacyl preoperatively
Study NCT01940692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.0g intra-articular Exacyl
Description: 3g Intra-articular Exacyl administration postoperatively
Study NCT04159051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Regional Hyperthermia
Description: Regional hyperthermia 1-2×/week to a total number of 7-10 treatments combined with salvage radiotherapy to a total dose of 70 Gy over 7 weeks
Study NCT03090893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATryn continuous infusion
Description: replenish serum thrombin levels
Study NCT04530357 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) The use of placebo: intramuscularly, twice, spaced 21 days apart, at a dose of 0.5 ml (22 volunteers)
Study NCT01215357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: 50mg tablets
Study NCT04289714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Electronic Monitoring Device
Description: Four Novel electronic Monitoring Devices were trialled
Study NCT01215357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ecopipam
Description: 50mg tablets
Study NCT01149213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: tDCS will be applied at 2mA/30 minutes, every other week during the first three months than once a month during the next three months.
Study NCT04454086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Undergo aerobic exercise
Study NCT04454086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Counseling
Description: Receive behavioral activity counseling
Study NCT04454086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Assessment
Description: Receive nutritional counseling
Study NCT04454086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04454086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04454086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Undergo resistance exercises
Study NCT00332605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone plus N-Acetyl Cysteine
Description: daily
Study NCT00332605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily
Study NCT04962438 — intervention group
Intervention type: DRUG
Intervention: Anti-VEGF
Description: Anti-tumor drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway
Study NCT04412590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vermont Family Based Approach
Description: Comprehensive and individualized program to promote emotional health and wellbeing in families using evidence-based health promotion, prevention and intervention.
Study NCT04412590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Pediatric care as usual.
Study NCT04535336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitality acupunch (VA) exercise program
Description: The VA had 3 phases and took 40 minutes to complete.
Study NCT04535336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants maintained their daily activities.
Study NCT01472562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Induction phase: 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~Maintenance phase: Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle.
Study NCT01472562 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Induction phase: Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.~Maintenance phase: Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52.
Study NCT02375282 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ambulation orderly
Description: The responsibility of the ambulation orderly is to walk patients after having a cardiac surgery, such as a coronary artery bypass surgery or a valve surgery. Baystate Medical Center hired an ambulation orderly May 8, 2013. The ambulation orderly is generally a high school graduate with some training in safe lifting and exercise, but extensive training is not required. In general, the goal is to have 1 ambulation orderly present 7 days a week for 8 hr per day. When available, ambulation orderlies are responsible for walking the patients who have been cleared by the clinical exercise physiologist or nurse up to 4 times per day. The walking of the patients occurs through the halls of the 6th floor of the Mass Mutual wing of Baystate Medical Center.
Study NCT04080310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin
Description: This study is a multicenter, randomized, open-label, parallel, phase IV trial. The study is planned to include 272 patients with clinical ASCVD requiring optimal statin therapy.~After enrollment, subjects are randomized into two groups in a 1:1 manner. patients in combination therapy group(rosuvastation 10mg and ezetimibe 10mg daily) will be provided a fixed-dose single pill comibation and patients in the intensive statin group will receive rosuvastatin 20mg daily.
Study NCT04080310 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin
Description: This study is a multicenter, randomized, open-label, parallel, phase IV trial. The study is planned to include 272 patients with clinical ASCVD requiring optimal statin therapy.~After enrollment, subjects are randomized into two groups in a 1:1 manner. patients in combination therapy group(rosuvastation 10mg and ezetimibe 10mg daily) will be provided a fixed-dose single pill comibation and patients in the intensive statin group will receive rosuvastatin 20mg daily.
Study NCT00868699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurasidone
Description: lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day
Study NCT00868699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurasidone
Description: lurasidone 20 mg/day for Days 1-7
Study NCT00868699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT01834222 — intervention group
Intervention type: BIOLOGICAL
Intervention: Non-intervention
Description: Non-intervention
Study NCT02665702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVB
Description: 25mg/m2 ，D1，8
Study NCT02665702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDP
Description: 75mg/m2 ，D1 or 25mg/m2 D1-3
Study NCT02665702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 15mg/d，d1-d7 civ
Study NCT04935723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: The study was conducted as a three-group interventional randomized controlled trial to examine the effect of Reiki touch therapy on surgical fear, pain, anxiety and vital signs in patients undergoing open abdominal surgery. Reiki was applied to the first group and sham reiki to the second group. Group 3 formed the control group.
Study NCT04935723 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reiki
Description: The study was conducted as a three-group interventional randomized controlled trial to examine the effect of Reiki touch therapy on surgical fear, pain, anxiety and vital signs in patients undergoing open abdominal surgery. Reiki was applied to the first group and sham reiki to the second group. Group 3 formed the control group.
Study NCT04406350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative tight control of respiratory end-tidal gases
Description: Control of ET CO2 and ET O2 during conduct of anesthesia.
Study NCT03892629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baduanjin exercise
Description: Participants received Baduanjin exercise. Each Baduanjin exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks
Study NCT03892629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Description: Participants received Baduanjin exercise. Each Baduanjin exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks
Study NCT03892629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Instrument rehabilitation
Description: Participants received pulmanory rehabilitation by using tri-ball respiratory trainer. Each instrument exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks
Study NCT04646135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg/ml
Description: Lorazepam will be administered intravenously according to the scheduled sequences.
Study NCT00524810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Caelyx 30 mg/m² day 1 every 3 weeks
Study NCT02221856 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motion View
Description: Motion View, a software we are using to place brackets virtually on a 3D rendition of a patients teeth, will be used to indirectly bond brackets onto patient's teeth with a 3D printed plastic transfer JIG in which the brackets will be precisely placed on the patients teeth according to the computer-guided software.
Study NCT02221856 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Orthodontic Treatment
Description: orthodontic treatment using non-customized brackets and stock wires
Study NCT04278378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: 1.6 mg riboflavin / day for 24 weeks
Study NCT04278378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: 1.6 mg riboflavin / day for 24 weeks
Study NCT04278378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: 0.4 mg folic acid / day for 24 weeks
Study NCT04278378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02904902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Subcutaneous Injection
Study NCT01375205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil Restoraderm
Description: Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
Study NCT01375205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subjects will apply Johnson\&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson\&Johnson cleanser.
Study NCT04441723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osteosynthesis with Gamma 3 nail , using a dynamic lag screw as a proximal fixation.
Description: Closed reduction and surgical stabilization of intertrochanteric hip fractures using Gamma 3 nail , with dynamic lag screw as proximal fixation
Study NCT04441723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osteosynthesis with Gamma 3 nail , using a static lag screw as a proximal fixation.
Description: Closed reduction and surgical stabilization of intertrochanteric hip fractures using Gamma 3 nail , with static lag screw as proximal fixation
Study NCT04453514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-informed yoga video recording
Description: Pre-recorded video of a 45-minute trauma-informed yoga practice. The yoga practice can be done standing or sitting in a chair. The yoga practice is comprised of slow, gentle movements combined with paying attention to the body and the breath. The practice uses invitational language and encourages participants to make choices and customize the movements according to their individual needs.
Study NCT03885011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSF-1
Description: This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
Study NCT03885011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSF-1 Component #1
Description: This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
Study NCT03885011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSF-1 Component #2
Description: This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
Study NCT01750736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Exercise and Manual Therapy
Description: Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform the augmented exercise at home and at each data collection session.
Study NCT01750736 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Exercise and Manual Therapy
Description: Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform general range of motion exercises for the neck at home and at each data collection session.
Study NCT00896428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyverapamil (gallopamil)
Description: 200 mg/day (1 tablet 100 mg morning and evening) for 12 months.
Study NCT00896428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo.
Description: 1 tablet morning and evening for 12 months
Study NCT04309929 — intervention group
Intervention type: DRUG
Intervention: Analgesics
Description: All patients will undergo the anesthesiological and surgical treatment provided for the patient's clinical conditions and in no case will the patients undergo a change in the normal diagnostic-therapeutic path due to participation in this study.
Study NCT01674621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide Transdermal (50 mcg)
Description: Abaloparatide Transdermal Microneedle Active Patch
Study NCT01674621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide Transdermal (100 mcg)
Description: Abaloparatide Transdermal Microneedle Active Patch
Study NCT01674621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide Transdermal (150 mcg)
Description: Abaloparatide Transdermal Microneedle Active Patch
Study NCT01674621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abaloparatide Injection (80 mcg)
Description: Abaloparatide Subcutaneous Injection
Study NCT01674621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abaloparatide Placebo
Description: Abaloparatide Transdermal Microneedle Placebo Patch
Study NCT03280082 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MUAC Program
Description: All children admitted to the PB program will receive standard care according to the national Protocol and that of MSF, including preventive and therapeutic care at admission as well as hospital care in case of clinical complications. There will be no change in the Protocol for the hospital care to the CRENI (Center of Intensive Nutritional Rehabilitation). RUTF (Ready-to-Use therapeutic food) will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
Study NCT03280082 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Program
Description: All children admitted to the standard program will receive standard care according to national and MSF protocols, including preventive and therapeutic care on admission as well as hospital care in case of clinical complications. RUTF will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
Study NCT01194128 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Support
Description: The intervention is comprised of three modules, each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
Study NCT01194128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information only control group
Description: Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include Caregiving and Depression, End of Life Decision Making, and Taking Care of You: Self-Care for Family Caregivers from the Family Caregiver Alliance; and Family Involvement in Nursing Home Care, Problem Solving, and Residents' Rights from the National Citizen's Coalition. Also provided will be a resource guide containing local contact information.
Study NCT02846116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic crown
Study NCT03494062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home-based exercise training
Study NCT01312987 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: Lipid-based nutritional supplement
Description: After gradual introduction of the lipid-based nutritional supplement, daily dose per child is as follows:~3 teaspoons 3 x day for children younger than 12 months 4.5 teaspoons 3 x day for children older than 12 months
Study NCT01312987 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid-based nutritional supplement
Description: After gradual introduction of the lipid-based nutritional supplement, daily dose per child is as follows:~3 teaspoons 3 x day for children younger than 12 months 4.5 teaspoons 3 x day for children older than 12 months